Welcome to chemicalbook!
+1 (818) 612-2111
Inquriy
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Rozanolixizumab
Rozanolixizumab
  • Rozanolixizumab

Rozanolixizumab NEW

Price $289 $619 $887
Package 1mg 5mg 10mg
Min. Order:
Supply Ability: 10g
Update Time: 2024-11-19

Product Details

Product Name: Rozanolixizumab CAS No.: 1584645-37-3
Purity: 95.9% (SEC-HPLC) Supply Ability: 10g
Release date: 2024/11/19

Product Introduction

Bioactivity

NameRozanolixizumab
DescriptionRozanolixizumab (RYSTIGGO) is a high-affinity humanized immunoglobulin G4 monoclonal antibody targeting Fc receptors (FcRn) in human newborns for the study of pathogenic IgG in autoimmune and alloimmune diseases.
In vitroDemonstrating similar affinity at both pH 6.0 (Kd 23 pM and 25 pM for human and cynomolgus monkey, respectively) and pH 7.4 (34 pM and 53 pM for human and cynomolgus monkey, respectively), Rozanolixizumab binds to human FcRn and cynomolgus monkey FcRn[1].In a dose-dependent manner, Rozanolixizumab is observed to inhibit the recycling of human IgG by human FcRn-transfected MDCK cells, with an IC50 of 0.41 nM. The recycling of IgG is similarly inhibited in cynomolgus monkey FcRn-transfected MDCK cells (IC50 0.98 nM)[1].Additionally, Rozanolixizumab causes an increase in intracellular IgG AF647[1].
In vivoDemonstrating non-linear pharmacokinetics indicative of target-mediated drug disposition, intravenous (IV) dosing of rozanolixizumab in cynomolgus monkeys showed that single IV doses (30 mg/kg) reduced plasma IgG concentration by 69% by Day 7 post-administration. Throughout the treatment period of 42 days, daily IV administration of rozanolixizumab (initial 30 mg/kg loading dose; 5 mg/kg daily thereafter) consistently reduced plasma IgG concentrations in all cynomolgus monkeys, maintaining low concentrations[1].
Storagestore at low temperature | store at -20°C | Shipping with blue ice.
KeywordsUCB-7665 | UCB 7665 | Rozanolixizumab

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$/
Anhui Ruihan Technology Co., Ltd
2023-08-21
  • Since: 2011-01-07
  • Address: 36 Washington Street, Wellesley Hills
INQUIRY